hold on there's just too much going on in Congress lmao...
Requires drug labels to show original manufacturer and supply chain details.
Senator Rick Scott (R-FL) introduced this bill with bipartisan support.
In committee, no Senate vote yet.
This bill, introduced by Senator Rick Scott of Florida, aims to update existing law to make drug labels more transparent. It proposes that medication packaging must identify the original manufacturers of the finished drug and its active ingredients. The bill is currently under review by the Senate Health, Education, Labor, and Pensions Committee, which will decide if it moves forward for a vote.
Introduced Feb 5, 2026
Senator Scott introduced this bill in the Senate on February 5, 2026, where it was assigned to the Committee on Health, Education, Labor, and Pensions. For the bill to progress, this committee must approve it, after which it could be considered for a vote by the full Senate. If passed by the Senate, it would then need to pass the House of Representatives and be signed by the President to become law.
If this bill passes, you would see more information on your medication labels, including who manufactured the finished product and who made each active ingredient. This data could also be available through QR codes or websites on the packaging. For pharmacists and bulk purchasers, active pharmaceutical ingredient (API) packaging would also require original manufacturer details. This increased transparency aims to give you a clearer picture of your medicine's origin.
Supporters Say
This bill would give consumers and healthcare providers more transparency about where drugs and their ingredients come from.
Critics Say
Some might argue that adding more information to labels or requiring electronic portals could increase costs for drug manufacturers.
Proponents believe that providing detailed manufacturing and supply chain information can enhance drug safety and consumer trust, helping to identify the source of medications. Concerns could arise about the administrative burden and costs for manufacturers to update labeling and create searchable electronic portals, which might be passed on to consumers as higher drug prices.